Diabetes Care, Vol 20, Issue 3 369-373, Copyright © 1997 by American Diabetes Association

ARTICLES

Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie

D Ziegler, H Schatz, F Conrad, FA Gries, H Ulrich and G Reichel
Diabetes-Forschungsinstitut an der Heinrich-Heine-Universitat, Dusseldorf, Germany.

OBJECTIVE: To evaluate the efficacy and safety of oral treatment with the antioxidant alpha-lipoic acid (ALA) in NIDDM patients with cardiac autonomic neuropathy (CAN), assessed by heart rate variability (HRV). RESEARCH DESIGN AND METHODS: In a randomized, double-blind placebo-controlled multicenter trial (Deutsche Kardiale Autonome Neuropathie [DEKAN] Study), NIDDM patients with reduced HRV were randomly assigned to treatment with daily oral dose of 800 mg ALA (n = 39) or placebo (n = 34) for 4 months. Parameters of HRV at rest included the coefficient of variation (CV), root mean square successive difference (RMSSD), and spectral power in the low-frequency (LF; 0.05-0.15 Hz) and high-frequency (HF; 0.15-0.5 Hz) bands. In addition, cardiovascular autonomic symptoms were assessed. RESULTS: Seventeen patients dropped out of the study (ALA n = 10; placebo n = 7). Mean blood pressure and HbA1 levels did not differ between the groups at baseline and during the study, but heart rate at baseline was higher in the group treated with ALA (P < 0.05). RMSSD increased from baseline to 4 months by 1.5 ms (-37.6 to 77.1) [median (minimum-maximum)] in the group given ALA and decreased by -0.1 ms (-19.2 to 32.8) in the placebo group (P < 0.05 for ALA vs. placebo). Power spectrum in the LF band increased by 0.06 bpm2 (-0. 09 to 0.62) in ALA, whereas it declined by -0.01 bpm2 (-0.48 to 1.86) in placebo (P < 0.05 for ALA vs. placebo). Furthermore, there was a trend toward a favorable effect of ALA versus placebo for the CV and HF band power spectrum (P = 0.097 and P = 0.094 for ALA vs. placebo). The changes in cardiovascular autonomic symptoms did not differ significantly between the groups during the period studied. No differences between the groups were noted regarding the rates of adverse events. CONCLUSIONS: These findings suggest that treatment with ALA using a well-tolerated oral dose of 800 mg/day for 4 months may slightly improve CAN in NIDDM patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. E. Maser, M. J. Lenhard, A. A. Rizzo, and A. A. Vasile Continuous Positive Airway Pressure Therapy Improves Cardiovascular Autonomic Function for Persons With Sleep-Disordered Breathing Chest, January 1, 2008; 133(1): 86 - 91. [Abstract] [Full Text] [PDF]

				Q. W. Shen, M. J. Zhu, J. Tong, J. Ren, and M. Du Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by {alpha}-lipoic acid in C2C12 myotubes Am J Physiol Cell Physiol, October 1, 2007; 293(4): C1395 - C1403. [Abstract] [Full Text] [PDF]

				R. E. Maser and M. J. Lenhard Cardiovascular Autonomic Neuropathy Due to Diabetes Mellitus: Clinical Manifestations, Consequences, and Treatment J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5896 - 5903. [Abstract] [Full Text] [PDF]

				J. Teichert, T. Tuemmers, H. Achenbach, C. Preiss, R. Hermann, P. Ruus, and R. Preiss Pharmacokinetics of Alpha-Lipoic Acid in Subjects With Severe Kidney Damage and End-Stage Renal Disease J. Clin. Pharmacol., March 1, 2005; 45(3): 313 - 328. [Abstract] [Full Text] [PDF]

				Z. Y. Fang, J. B. Prins, and T. H. Marwick Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications Endocr. Rev., August 1, 2004; 25(4): 543 - 567. [Abstract] [Full Text] [PDF]

				A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman Oxidative Stress in the Pathogenesis of Diabetic Neuropathy Endocr. Rev., August 1, 2004; 25(4): 612 - 628. [Abstract] [Full Text] [PDF]

				J. Teichert, R. Hermann, P. Ruus, and R. Preiss Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha-Lipoic Acid following Oral Administration in Healthy Volunteers J. Clin. Pharmacol., November 1, 2003; 43(11): 1257 - 1267. [Abstract] [Full Text] [PDF]

				R. E. Maser, B. D. Mitchell, A. I. Vinik, and R. Freeman The Association Between Cardiovascular Autonomic Neuropathy and Mortality in Individuals With Diabetes: A meta-analysis Diabetes Care, June 1, 2003; 26(6): 1895 - 1901. [Abstract] [Full Text] [PDF]

				P. Kempler Review: Autonomic neuropathy: a marker of cardiovascular risk The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 84 - 90. [Abstract] [PDF]

				A. S. Ametov, A. Barinov, P. J. Dyck, R. Hermann, N. Kozlova, W. J. Litchy, P. A. Low, D. Nehrdich, M. Novosadova, P. C. O'Brien, et al. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With {alpha}-Lipoic Acid: The SYDNEY Trial Diabetes Care, March 1, 2003; 26(3): 770 - 776. [Abstract] [Full Text] [PDF]

				N. Dicter, Z. Madar, and O. Tirosh {alpha}-Lipoic Acid Inhibits Glycogen Synthesis in Rat Soleus Muscle via Its Oxidative Activity and the Uncoupling of Mitochondria J. Nutr., October 1, 2002; 132(10): 3001 - 3006. [Abstract] [Full Text] [PDF]

				R. C. Ruhe and R. B. McDonald Use of Antioxidant Nutrients in the Prevention and Treatment of Type 2 Diabetes J. Am. Coll. Nutr., October 1, 2001; 20(90005): 363S - 369. [Abstract] [Full Text]

				D. Manzella, M. Barbieri, E. Ragno, and G. Paolisso Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes Am. J. Clinical Nutrition, June 1, 2001; 73(6): 1052 - 1057. [Abstract] [Full Text] [PDF]